8-K: CareMax Secures $20 Million in New Debt Financing, Amends Credit Agreement

CareMax, Inc. has entered into an agreement for $20 million in new term loans and amended its existing credit agreement, including a waiver of certain defaults until August 15, 2024.

Summary

• CareMax, Inc. has secured a new $4.0 million term loan and a $16.0 million delayed draw term loan facility, totaling $20 million in new debt financing.
• The new loans, referred to as the Eighth Amendment Loans, will mature on the earlier of April 10, 2025, or the occurrence of certain liquidity events.
• These loans will bear interest at a rate of Term SOFR plus 13.00% per annum, with a 6.50% per annum fee on the unused portion of the commitments.
• Both the interest and the unused commitment fee will be capitalized and added to the outstanding loan balance.
• Lenders received a 3% upfront fee, also capitalized, and are guaranteed a minimum total cash return of 130% on funded amounts.
• The agreement requires CareMax to maintain a minimum liquidity level and operate within a maximum variance to budget.
• The company must use net cash proceeds from Medicare Shared Savings Program receivables to prepay outstanding loans.
• The agreement also extends a waiver of certain defaults under the existing credit agreement until August 15, 2024, subject to earlier termination under specific conditions.

Sentiment

Score: 3

Explanation: The document indicates financial strain due to the high cost of debt and restrictive terms, despite securing necessary funding. The need for a waiver of defaults and the high cost of capital are concerning.

Positives

• CareMax has successfully secured additional financing of $20 million, providing immediate capital.
• The extension of the waiver of certain defaults provides the company with additional time to address its financial obligations.
• The delayed draw term loan facility provides flexibility in accessing additional capital as needed.

Negatives

• The new loans carry a high interest rate of Term SOFR plus 13.00%, increasing the company's debt servicing costs.
• The 6.50% fee on unused commitments adds to the overall cost of the financing.
• The minimum 130% return for lenders indicates a significant cost of capital for CareMax.
• The requirement to use Medicare Shared Savings Program receivables to prepay loans could limit the company's cash flow flexibility.

Risks

• The high interest rate and fees on the new loans could strain CareMax's financial resources.
• The requirement to maintain minimum liquidity and operate within budget could limit the company's operational flexibility.
• The waiver of defaults is only temporary and subject to early termination, creating uncertainty.
• The company's ability to repay the loans by April 10, 2025, or upon a liquidity event, is not guaranteed.

Future Outlook

The company will need to manage its cash flow carefully to meet the repayment obligations of the new loans and operate within the constraints of the amended credit agreement. The company will also need to address the underlying issues that led to the need for the waiver of defaults.

Management Comments

• The document does not contain any direct quotes from management, but the signing of the agreement by Kevin Wirges, Executive Vice President, Chief Financial Officer and Treasurer, indicates management's approval and involvement.

Industry Context

The healthcare industry, particularly companies focused on Medicare and value-based care, often require significant capital to support growth and operations. This financing agreement suggests CareMax is actively managing its financial needs in a competitive environment.

Comparison to Industry Standards

• The interest rate of Term SOFR plus 13.00% is relatively high, suggesting that CareMax may have limited access to lower-cost financing options. This is not uncommon for companies with higher risk profiles or those in a turnaround phase.
• The 130% minimum return for lenders is also high, indicating a significant cost of capital. This is higher than typical rates for established healthcare companies with strong credit ratings.
• Other healthcare companies, such as Oak Street Health (now part of CVS Health) and Agilon Health, have also utilized debt financing, but their terms may differ based on their financial health and market position.
• The requirement to use Medicare Shared Savings Program receivables to prepay loans is a specific condition that may not be standard across all healthcare financing agreements, reflecting CareMax's specific financial situation.

Stakeholder Impact

• Shareholders may be concerned about the increased debt burden and the high cost of financing.
• Employees may be affected by any cost-cutting measures implemented to meet the financial obligations.
• Customers may not be directly impacted, but the company's financial health could indirectly affect service quality.
• Suppliers and creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• CareMax will need to manage its cash flow to meet the repayment obligations of the new loans.
• The company will need to operate within the constraints of the amended credit agreement, including maintaining minimum liquidity and operating within budget.
• CareMax will need to address the underlying issues that led to the need for the waiver of defaults.
• The company will file the full text of the Eighth Amendment as an exhibit to its Quarterly Report on Form 10-Q for the period ending September 30, 2024.

Key Dates

Keywords

debt financing, term loan, credit agreement, waiver, liquidity, CareMax, Medicare Shared Savings Program, Term SOFR